Intra-Cellular Therapies Total Liabilities and Share Holders Equity 2013-2024 | ITCI

Intra-Cellular Therapies total liabilities and share holders equity for the quarter ending September 30, 2024 was $1.324B, a 84.55% increase year-over-year.

  • Intra-Cellular Therapies total liabilities and share holders equity for 2023 was $0.728B, a 3.51% decline from 2022.
  • Intra-Cellular Therapies total liabilities and share holders equity for 2022 was $0.755B, a 54.06% increase from 2021.
  • Intra-Cellular Therapies total liabilities and share holders equity for 2021 was $0.49B, a 31.7% decline from 2020.

Intra-Cellular Therapies Total Liabilities and Share Holders Equity 2013-2024 | ITCI

  • Intra-Cellular Therapies total liabilities and share holders equity for 2023 was $0.728B, a 3.51% decline from 2022.
  • Intra-Cellular Therapies total liabilities and share holders equity for 2022 was $0.755B, a 54.06% increase from 2021.
  • Intra-Cellular Therapies total liabilities and share holders equity for 2021 was $0.49B, a 31.7% decline from 2020.